19 completed, 5 terminated, 1 not yet recruiting, 1 recruiting. 27 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Completed 19, Terminated 5, Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 3 | 4 | Completed 3, Unknown 1 |
| Phase 1 | 2 | Completed 1, Not yet recruiting 1 |
Follow Telmisartan: new trials by email Literature Review of Telmisartan trials Research Report on Telmisartan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients Telmisartan, Doxorubicin (DOX) - Breast Cancer, Doxorubicin Induced Cardiomyopathy | Phase 1 / Phase 2 | Not yet recruiting | Tanta University | 36 | 2026-02-01 | 2026-01-29 |
| Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer Telmisartan - Ovarian Cancer | Phase 2 | Recruiting | Tyler J Curiel | 33 | 2026-01-21 | 2026-01-28 |
| Efficacy and Safety of HB-1 for Panic Disorder HB-1, Telmisartan Only Product in Oral Dose Form, Verapamil Only Product in Oral Dose Form - Panic Disorder, Mental Illness | Phase 2 | Terminated | HB BioTech, LLC | 170 | 2024-10-29 | 2026-09-24 |
| INvestigating TELmisartin Study Telmisartan Oral Product, Placebo - Covid19 | Phase 2 | Terminated | University of Hawaii | 24 | 2021-09-01 | 2022-07-01 |
| Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection Nitazoxanide and Ciclésonide, Telmisartan 20Mg Oral Tablet, Paracetamol - Covid19, Covid19 Drug Treatment | Phase 2 / Phase 3 | Unknown | ANRS, Emerging Infectious Diseases | 600 | 2021-04-12 | 2023-01-31 |
| Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet, Telmisartan 40Mg Oral Tablet, Atorvastatin 20 Mg Oral Tablet - COVID-19, COVID-19 Drug Treatment | Phase 2 / Phase 3 | Completed | ANRS, Emerging Infectious Diseases | 294 | 2020-11-27 | 2024-12-27 |
| Telmisartan in Respiratory Failure Due to COVID-19 Telmisartan - COVID-19, Respiratory Insufficiency | Phase 2 | Completed | Abraham Edgar Gracia-Ramos | 66 | 2020-08-12 | 2023-10-05 |
| Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation Vitamins, Telmisartan, Ciclesonide - Corona Virus Infection, Sars-CoV2 | Phase 2 / Phase 3 | Completed | University Hospital, Bordeaux | 412 | 2020-07-29 | 2026-05-12 |
| Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients Telmisartan 40mg, Placebo - COVID-19 | Phase 2 | Terminated | University of Hawaii | 24 | 2020-07-01 | 2023-08-21 |
| Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel) Telmisartan tablets - Neuropathic Pain, Chemotherapy Effect | Phase 2 | Completed | Dr. Frank Behrens | 35 | 2020-04-09 | 2024-08-28 |
| Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension AD209, Amlodipine low, Amlodipine high - Hypertension,Essential | Phase 2 | Completed | Addpharma Inc. | 176 | 2020-02-25 | 2021-07-21 |
| Telmisartan Pilot Study on Treatment Resistant Schizophrenia Telmisartan Pill - Schizophrenia, Schizo Affective Disorder | Phase 2 | Terminated | Xiaoduo Fan | 6 | 2019-02-01 | 2022-03-02 |
| Health Evaluation in African Americans Using RAS Therapy Telmisartan 20mg, Telmisartan 40mg, Placebo - Alzheimer's Disease | Phase 1 / Phase 2 | Completed | Emory University | 61 | 2015-04-01 | 2024-05-23 |
| Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis TDF/3TC/EFV + Telmisartan, TDF/3TC/EFV only - Acute HIV Infection, HIV CNS Involvement | Phase 2 | Completed | SEARCH Research Foundation | 21 | 2015-01-01 | 2019-09-19 |
| Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients Perindopril, Telmisartan - Alzheimer's Disease | Phase 2 | Terminated | Sunnybrook Health Sciences Centre | 23 | 2014-03-01 | 2025-05-06 |
| Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study) Telmisartan - HIV-1 Infection | Phase 2 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 58 | 2014-01-01 | 2021-08-03 |
| A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease Telmisartan - Endothelial Dysfunction | Phase 2 | Completed | University of California, Los Angeles | 17 | 2012-08-01 | 2014-12-08 |
| CKD-828 Primary Hypertension Trial(Dose-selection) S-Amlodipine, Telmisartan, S-Amlodipine, Telmisartan - Hypertension | Phase 2 | Completed | Chong Kun Dang Pharmaceutical | 430 | 2010-07-01 | 2011-04-26 |
| HIV and Fat Accumulation Telmisartan - HIV Infection | Phase 2 | Completed | University of California, Los Angeles | 35 | 2010-05-01 | 2019-02-04 |
| Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients Aliskiren/ Valsartan, Telmisartan/ Ramipril - Hypertension | Phase 2 | Completed | Novartis Pharmaceuticals | 88 | 2009-07-01 | 2016-11-18 |
Showing 20 of 27. Sign in to see all of them.
Hypertension (7) · COVID-19 (5) · Alzheimer Disease (2) · Breast Neoplasms (2) · Essential Hypertension (2) · Ovarian Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Coronavirus Infections (1) · Diabetes Mellitus (1) · HIV Infections (1) · Heart Diseases (1) · Heart Failure (1) · Inflammation (1)
Boehringer Ingelheim (5) · ANRS, Emerging Infectious Diseases (2) · University of California, Los Angeles (2) · University of Hawaii (2) · Abraham Edgar Gracia-Ramos (1) · Addpharma Inc. (1) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Chong Kun Dang Pharmaceutical (1) · Dr. Frank Behrens (1) · Emory University (1) · HB BioTech, LLC (1) · Mario Negri Institute for Pharmacological Research (1) · Medical University of Vienna (1) · Novartis Pharmaceuticals (1) · SEARCH Research Foundation (1)
United States (9) · Canada (2) · Germany (2) · Italy (2) · South Korea (2) · Australia (1) · Austria (1) · Burkina Faso (1) · Côte d’Ivoire (1) · Denmark (1) · Egypt (1) · France (1) · Guinea (1) · Japan (1) · Mexico (1)
Abraham Edgar Gracia-Ramos, MD MSc (1) · Cecilia M Shikuma (1) · Cecilia M Shikuma, MD (1) · ChangGu Park, M.D., Ph.D (1) · Ivy Wilkinson-Ryan, MD (1) · Jordan E. Lake, MD (1) · Jordan E. Lake, MD, MSc (1) · Jordan Lake, M.D. (1) · Krista Lanctot, PhD (1) · Martin Clodi, MD (1) · Martin P Huelsmann, MD (1) · Martin Sebastian, MD (1)
PMID 17389151, PMID 23516440, PMID 23810874, PMID 27658740, PMID 33050924, PMID 34473343, PMID 36094783, PMID 36574985, PMID 38454482, PMID 39082471, PMID 39443527
1RF1AG051514 (1), 2008 (1), R01NS084911 (1), U54MD007601 (1), UM1AI068636 (1)